Apertura Gene Therapy Email Format

Biotechnology ResearchNew York, United States2-10 Employees

Apertura Gene Therapy is a biotechnology company focused on developing next-generation adeno-associated virus (AAV) gene therapies to address diseases with limited treatment options. The company advances programs by engineering multiple components of gene delivery to overcome existing barriers in genetic medicine, aiming to enable systemic and central nervous system delivery. Its work is grounded in technologies from the Broad Institute and Harvard University, and the organization operates from New York, New York. Apertura has pursued collaborations and partnerships to progress therapeutic programs, including efforts related to tuberous sclerosis complex (TSC), and has engaged with multiple collaborators to advance TfR1 CapX, a platform describing its approach to delivery. Recent activities include partnerships and program developments announced in 2026, reflecting ongoing collaboration with patient-focused organizations and participation in scientific meetings. The firm positions itself within the biotechnology research sector, emphasizing the development of gene therapies and delivery technologies to expand treatment possibilities for serious genetic diseases.

Get verified Apertura Gene Therapy emails free

Company overview Employee directory